KODHealthcare · BiotechnologyThe 7 Wall Street analysts covering Kodiak Sciences, Inc. hold a median 12-month price target of $122 — +39.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 24 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Kodiak Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KOD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.2% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $96 → $126 |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $58 → $96 |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Sept 2026 | LifeSci Capital | Maintains | Outperform | — |
| 28 Sept 2026 | LifeSci Capital | Maintains | Outperform | $85 → $145 |
| 28 Sept 2026 | UBS | Maintains | Buy | $80 → $120 |
| 28 Sept 2026 | UBS | Maintains | Buy | — |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Neutral | $36 |
| 17 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $58 |
| 17 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $58 |
| 17 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 3 Aug 2026 | JP Morgan | Maintains | Overweight | $56 → $66 |
| 11 May 2026 | Chardan Capital | Upgrade | Buy | — |
| 11 May 2026 | Chardan Capital | Upgrade | Buy | $14 → $61 |
| 27 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2026 | UBS | Maintains | Buy | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KOD appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Kodiak Sciences, Inc. returned +412.2% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 2% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kodiak Sciences, Inc. has a market value of $5.5B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$242.0M.
Diluted earnings per share, trailing twelve months: $−4.19.
Free cash flow in the twelve months to 30 June 2026: −$159.9M.
Trailing P/E: −20.3×; forward P/E: −25.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kodiak Sciences, Inc. employs 141 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kodiak Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks reports that Kodiak Sciences’ Zenkuda has shown promise across three retinal diseases, supported by positive Phase III data. The company plans to file for regulatory approval in 2026.
Why it matters — The reported clinical results and planned filing are relevant to KOD watchers tracking Zenkuda’s potential across multiple indications and its development timeline.
Schaeffers Research published a list titled “11 Stocks Most Likely to See a Short Squeeze Rally.” Its excerpt says bond yields, oil prices and inflation rhetoric are making conditions challenging for investors ahead of earnings season.
Why it matters — The excerpt provides no KOD-specific detail, so it offers little direct information for Kodiak Sciences watchers.
Kodiak Sciences plans to present clinical data from all three late-stage programs at AAO 2026. The presentations will include the first Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration, Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, and Phase 1b APEX data for KSI-101 in inflammation-related macular edema.
Why it matters — The presentations will provide updates on clinical programs spanning several retinal conditions, including first scientific disclosure of the DAYBREAK Phase 3 results.
Kodiak Sciences reported that its Phase III DAYBREAK study met primary endpoints for two investigational wet AMD treatments in treatment-naïve patients. Both therapies demonstrated statistical equivalence to aflibercept on visual-acuity outcomes.
Why it matters — A Kodiak watcher would care because positive Phase III results for its pipeline candidates in wet AMD support the company's development progress in a major indication.
Kodiak Sciences' stock tripled in a single session after its eye drug cleared a pivotal trial. However, the company remains a cash-burning biotech with no revenue, and a likely share offering complicates the outlook.
Why it matters — A KOD watcher would care because the drug trial success drove a massive one-day stock surge, but the company's lack of revenue and probable share offering raise questions about the sustainability of the move.
The 7 Wall Street analysts covering Kodiak Sciences, Inc. have a median 12-month price target of $122, with estimates ranging from $103 to $145. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Kodiak Sciences, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kodiak Sciences, Inc. 49 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Kodiak Sciences, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +39.2% from the last close, and Ticker Nerd's factor model ranks Kodiak Sciences, Inc. 49 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kodiak Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KOD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $103 to $145 over the next 12 months.
Kodiak Sciences, Inc. returned +412.2% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases.
The most recent item we track (Zacks Investment Research, 19 Oct 2026): "Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?". Zacks reports that Kodiak Sciences’ Zenkuda has shown promise across three retinal diseases, supported by positive Phase III data. The company plans to file for regulatory approval in 2026.
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on ophthalmology and retinal vascular disorders. Its current programs include late-stage and earlier-stage candidates built around its proprietary Antibody Biopolymer Conjugate platform, which is designed to support the development of next-generation eye medicines. Kodiak Sciences Inc. serves the biopharmaceutical and ophthalmic research markets by advancing specialized therapeutics for diseases such as wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy. Headquartered in Palo Alto, California, and founded in 2009, the company remains focused on researching, developing, and commercializing retina-directed medicines for patients and eye-care specialists.
CEO Dr. Victor Perlroth M.D. · 141 employees · United States · https://kodiak.com
